Dr. Nora Volkow

Federally funded survey data provided by the University of Michigan indicates that teen marijuana use has declined significantly over the past decade and is now at historic lows. Consistent with data previously reported by the Centers for Disease Control and Prevention and the ...

People prescribed Ozempic or Wegovy are less likely to develop a cannabis use disorder or relapse from the condition than those who take other diabetes or obesity medications, reported the NewScientist on Thursday. As brand names for the compound semaglutide, Ozempic and Wegovy are said to reduce...

Approximately 11% of 12th-grade students across the U.S. reported past-year use of delta-8- tetrahydrocannabinol (AKA delta-8-THC, or delta-8), according to data analysis from the 2023 Monitoring the Future survey, conducted by researchers at the University of Michigan, Ann Arbor and funded by...

Nora Volkow, the director of the National Institute on Drug Abuse (NIDA), said that psychedelic substances have promising potential for therapeutic uses, particularly for treating severe depression, post-traumatic stress disorder (PTSD) and addiction. Accelerating Research At a...

According to Nora Volkow, director of the National Institute on Drug Abuse (NIDA), treating addiction as a criminal matter is ineffective and should instead be viewed as a public health issue. NIDA aims to advance science on the causes and consequences of drug use and addiction...

Ongoing discussions on whether psychedelics can help treat mental health conditions and improve quality of life have compelled officials and researchers to seek public opinion. All psychedelics are listed as Schedule I substances though the FDA classified psychedelic-assisted...

This week, an annual drug use survey Monitoring the Future (MTF), conducted by scientists at the University of Michigan’s Institute for Social Research, Ann Arbor revealed that cannabis and hallucinogen use by young adults (19-30) in the past year reached a historic...

As David Hodes first noted in The Green Market Report, the U.S. National Institutes of Health (NIH)’s growing interest in psychedelic studies is remarkable.  The agency annually invests about $41.7 billion in medical research as a whole, while more than 80 percent of the funding is...

Cannabis consumers who tend to choose high potency weed for their pleasure, are at higher risk of becoming addicted or developing marijuana-caused psychosis, a new study shows. “Overall, use of higher potency cannabis, relative to lower potency cannabis, was associated with an increased risk...

As states legalize marijuana, some as long as 10 years ago, many are beginning to realize the public health and safety implications of a variety of new high-potency products as questions about possible links to psychosis arise.  MMJ BioPharma Labs is positioned to perform...